MIG

MIG AG, based in Munich, Germany, is a prominent venture capital firm investing primarily in deep tech and life sciences. Their notable portfolio includes BioNTech, renowned for its COVID-19 vaccine, and companies like German Bionic, developing exoskeletons, and iOmx Therapeutics, focusing on novel cancer treatments. With over €1.2 billion in committed capital, MIG AG targets early to mid-stage startups that drive technological advancements and societal benefits. Their strategy is to invest in companies with groundbreaking innovations in biopharmaceuticals, medical technology, digital health, advanced computing, and environmental tech. MIG AG is known for its rigorous due diligence and active involvement in portfolio companies, providing strategic support and leveraging an extensive network to foster growth. Key team members include co-founders Jürgen Kosch and Michael Motschmann, both based in Munich, who bring decades of experience in venture capital and entrepreneurship. Startups can approach MIG AG through direct contact or their extensive industry network, emphasizing innovative solutions with strong growth potential. For entrepreneurs seeking investment, MIG AG values clear, impactful pitches that demonstrate significant technological breakthroughs and market readiness.